Status:

COMPLETED

Safety of HEPLISAV™ Hepatitis B Virus Vaccine in End-stage Kidney Failure Patients

Lead Sponsor:

Dynavax Technologies Corporation

Conditions:

Hepatitis B

Eligibility:

All Genders

40+ years

Phase:

PHASE1

Brief Summary

The purpose of this study is to find out if a new investigational hepatitis B virus vaccine, HEPLISAV™, is safe in patients at least 40 years of age who have progressive loss of kidney function with m...

Detailed Description

Infection with hepatitis B virus (HBV) is a major global health problem. Worldwide, it is estimated that 2 billion people have been infected previously and 350 million are chronically infected. About ...

Eligibility Criteria

Inclusion

  • Willing and able to give written informed consent
  • Progressive loss of kidney function with more advanced stage 3 (GFR at least 45 mL/min) or stage 4 chronic kidney disease by National Kidney Foundation classification, and are expected to eventually go on hemodialysis
  • Body mass index of 31 or less

Exclusion

  • Received previous vaccination with any HBV vaccine (1 or more doses)
  • Any history of HBV infection
  • Pregnant or breast-feeding, or planning a pregnancy during the study
  • Has autoimmune disease
  • Diagnosis of chronic kidney failure due to autoimmune disease
  • Receiving hemodialysis treatment at the time of enrollment
  • Received any blood products or antibodies within 3 months prior to study entry, or is likely to require blood products during the study
  • Ever received an injection with DNA plasmids or oligonucleotides
  • Received erythropoietin within 7 days prior to the first study injection
  • Received vaccination with any vaccines during the 4 weeks prior to study entry
  • Received any other investigational medicinal agent during the 4 weeks prior to study entry

Key Trial Info

Start Date :

January 1 2006

Trial Type :

INTERVENTIONAL

Allocation :

ACTUAL

End Date :

March 1 2008

Estimated Enrollment :

42 Patients enrolled

Trial Details

Trial ID

NCT00426712

Start Date

January 1 2006

End Date

March 1 2008

Last Update

March 20 2019

Active Locations (4)

Enter a location and click search to find clinical trials sorted by distance.

Page 1 of 1 (4 locations)

1

West Coast Clinical Trials

Costa Mesa, California, United States, 92626

2

Twin Cities Clinical Research

Brooklyn Center, Minnesota, United States, 55430

3

Covance

Austin, Texas, United States, 78727

4

University of Virginia Health System, Nephrology Clinical Research Center

Charlottesville, Virginia, United States, 22908

Safety of HEPLISAV™ Hepatitis B Virus Vaccine in End-stage Kidney Failure Patients | DecenTrialz